Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Peptide-based metabolic research has accelerated rapidly across Canada, especially in studies involving incretin analogues, amylin analogues, mitochondrial peptides, growth-hormone-related compounds and cellular metabolism modulators. This 2026 guide reviews the most studied peptide categories in fat-loss and body-composition research, including retatrutide, tirzepatide, cagrilintide, tesamorelin, MOTS-C, SS-31, 5-Amino-1MQ and NAD+, while keeping the discussion strictly research-use-only and compliance-safe.
The peptides most studied in fat-loss and metabolic research include incretin-pathway compounds such as retatrutide and tirzepatide, amylin-pathway compounds such as cagrilintide, GHRH analogues such as tesamorelin, mitochondrial peptides such as MOTS-C and SS-31, and cellular metabolism compounds such as 5-Amino-1MQ and NAD+. These compounds are not direct “fat burners.” They are studied for effects on appetite signaling, glucose regulation, energy expenditure, visceral adiposity, mitochondrial function, adipocyte biology and metabolic flexibility.
Fat-loss peptide research is not one single category. It includes multiple pathway families that influence body-composition models through different mechanisms. Some compounds are studied through appetite and incretin signaling. Others are studied through mitochondrial energy systems, adipocyte enzyme activity, visceral fat models, or recovery-related pathways that may affect training capacity in research settings.
The best way to understand “fat-loss peptides” in research is to separate the pathway being studied. Retatrutide and tirzepatide are incretin-pathway models. Cagrilintide is an amylin-pathway model. Tesamorelin is a GHRH and visceral-adiposity model. MOTS-C and SS-31 are mitochondrial-energy models. 5-Amino-1MQ and NAD+ are cellular-metabolism models.
For Canadian researchers, the most important supplier evaluation factors are purity, identity confirmation, batch-specific COAs, transparent storage guidance, clear research-use-only labeling and conservative scientific language that avoids consumer-use or treatment claims.
Metabolic peptides are studied across several distinct mechanistic classes. These classes should not be treated as interchangeable.
| Research Pathway | Representative Compounds | Primary Research Focus |
|---|---|---|
| Incretin and appetite signaling | Retatrutide, tirzepatide, semaglutide-like comparators | GLP-1, GIP and glucagon receptor biology, satiety signaling, glucose regulation, gastric kinetics and energy-balance models. |
| Amylin and satiety axis | Cagrilintide, CagriSema research context | Satiety signaling, gastric-emptying models, caloric-intake research and GLP-1 plus amylin combination models. |
| Visceral adiposity and GH-axis research | Tesamorelin, CJC-1295 / Ipamorelin, Ipamorelin | Visceral adipose tissue, IGF-1 signaling, body-composition research and growth-hormone pathway models. |
| Mitochondrial energy systems | MOTS-C, SS-31 | Mitochondrial function, oxidative stress, exercise adaptation, metabolic flexibility and energy-handling research. |
| Cellular metabolism and adipocyte biology | 5-Amino-1MQ, NAD+ | NNMT inhibition, NAD+ metabolism, adipocyte signaling, cellular energy balance and metabolic health research. |
| Recovery-supporting research | BPC-157, TB-500 | Tissue repair, angiogenesis, cellular migration and recovery-model research that may indirectly affect activity-related metabolic models. |
The compounds below are among the most discussed peptides and peptide-adjacent compounds in Canadian metabolic, body-composition and energy-balance research.
| Compound | Research Class | Why Researchers Study It |
|---|---|---|
| Retatrutide | Triple GIP, GLP-1 and glucagon receptor agonist | Studied for multi-receptor metabolic signaling, body-weight models, energy expenditure, liver-fat biology and advanced incretin research. |
| Tirzepatide | Dual GIP and GLP-1 receptor agonist | Studied as a dual-incretin model and major comparator against GLP-1-only and triple-agonist research compounds. |
| Cagrilintide | Long-acting amylin analogue | Studied for satiety, appetite regulation, gastric-emptying models and GLP-1 plus amylin combination research. |
| Tesamorelin | Growth hormone-releasing hormone analogue | Studied for visceral adipose tissue, liver-fat research, IGF-1 signaling and body-composition models. |
| MOTS-C | Mitochondrial-derived peptide | Studied for metabolic flexibility, insulin sensitivity models, exercise adaptation and cellular energy signaling. |
| SS-31 | Mitochondria-targeting peptide | Studied for cardiolipin interaction, mitochondrial efficiency, oxidative stress and energy-system integrity. |
| 5-Amino-1MQ | NNMT inhibitor | Studied for adipocyte metabolism, NNMT-related energy balance and cellular metabolic remodeling. |
| NAD+ | Cellular redox and mitochondrial cofactor | Studied for mitochondrial energy metabolism, cellular redox balance, sirtuin biology and metabolic aging pathways. |
| CJC-1295 / Ipamorelin | Growth hormone pathway research blend | Studied in growth hormone secretion, IGF-1 signaling and body-composition pathway research. |
| BPC-157 and TB-500 | Repair and recovery model peptides | Not direct metabolic peptides, but studied in recovery and tissue-model pathways that can intersect with activity-related research designs. |
The strongest research comparison separates the compounds by receptor target, evidence maturity and primary experimental question.
| Compound | Main Pathway | Evidence Strength | Best Research Question |
|---|---|---|---|
| Retatrutide | GIPR, GLP-1R and glucagon receptor | Strong clinical research momentum with Phase 2 data and Phase 3 topline readouts | What happens when a metabolic model activates three major receptor pathways at once? |
| Tirzepatide | GIPR and GLP-1R | Very strong clinical research and approved-drug comparator literature | How does dual GIP and GLP-1 activation differ from GLP-1-only signaling? |
| Cagrilintide | Amylin receptor pathway | Growing clinical and combination-trial literature | How does amylin-pathway satiety research interact with GLP-1 pathway research? |
| Tesamorelin | GHRH and GH/IGF-1 axis | Strong visceral-adiposity evidence in specific clinical research populations | How can visceral adipose tissue be studied through GH-axis signaling? |
| MOTS-C | Mitochondrial and AMPK-related pathways | Preclinical and early translational research | How do mitochondrial-derived peptides influence metabolic flexibility? |
| SS-31 | Mitochondrial cardiolipin and oxidative stress | Preclinical, translational and mitochondrial-disease research context | How does mitochondrial membrane support affect energy-system function? |
| 5-Amino-1MQ | NNMT inhibition and adipocyte metabolism | Preclinical and mechanistic research | How does NNMT inhibition affect adipocyte energy handling? |
| NAD+ | Cellular redox and mitochondrial cofactor biology | Broad foundational metabolism literature | How does NAD+ biology affect cellular energy, redox balance and mitochondrial signaling? |
For incretin-based metabolic research, retatrutide and tirzepatide are the most advanced pathway models. For satiety-axis research, cagrilintide is highly relevant. For visceral-fat pathway research, tesamorelin has a specific evidence base. For mitochondrial and cellular metabolism research, MOTS-C, SS-31, 5-Amino-1MQ and NAD+ provide different non-incretin models.
The research literature varies widely by compound. Some compounds have mature clinical trial literature, while others remain primarily preclinical or mechanistic.
| Compound | Key Evidence Context | Interpretation Limit |
|---|---|---|
| Retatrutide | A Phase 2 obesity trial reported large body-weight reductions with a triple-hormone receptor agonist, and TRIUMPH-4 later provided Phase 3 topline context in obesity or overweight with knee osteoarthritis. | Still investigational. Sponsor topline results and full peer-reviewed publications should be interpreted separately. |
| Tirzepatide | SURMOUNT-1 and related studies established tirzepatide as a major dual-incretin comparator in obesity and type 2 diabetes research. | Approved finished-drug data should not be converted into instructions for research materials. |
| Cagrilintide | Cagrilintide and cagrilintide-semaglutide studies support amylin-pathway and combination research interest. | Combination studies must be distinguished from standalone research material claims. |
| Tesamorelin | Clinical studies reported reductions in visceral adipose tissue and liver-fat-related endpoints in specific HIV-associated lipodystrophy research populations. | The evidence is population-specific and should not be generalized into broad weight-loss claims. |
| MOTS-C | Foundational research identified MOTS-C as a mitochondrial-derived peptide involved in metabolic homeostasis and exercise-related signaling. | Much of the evidence is mechanistic, preclinical or early translational. |
| SS-31 | SS-31 has been studied for mitochondrial membrane, cardiolipin and oxidative-stress pathway support in aging and disease models. | Not a fat-loss compound. Its relevance is mitochondrial energy-system research. |
| 5-Amino-1MQ | NNMT inhibition has been linked to adipocyte metabolism, energy expenditure and diet-induced obesity models in preclinical literature. | Evidence is not equivalent to mature incretin clinical trial literature. |
| NAD+ | NAD+ biology is central to mitochondrial metabolism, redox reactions, sirtuin signaling and metabolic aging research. | NAD+ is a broad cellular cofactor, not a direct fat-loss peptide. |
A useful research framework starts with the pathway being studied rather than asking which compound is “best.”
| Research Goal | Most Relevant Compounds | Why |
|---|---|---|
| Multi-receptor metabolic signaling | Retatrutide | Targets GIPR, GLP-1R and glucagon receptor pathways in one investigational compound. |
| Dual incretin comparison | Tirzepatide | Useful as a GIP and GLP-1 receptor comparator against GLP-1-only and triple-agonist models. |
| Satiety-axis and amylin research | Cagrilintide | Represents the amylin analogue pathway and combination research with GLP-1 analogues. |
| Visceral adipose tissue models | Tesamorelin | Has specific literature around visceral adiposity in defined clinical research populations. |
| Mitochondrial metabolic flexibility | MOTS-C | Studied as a mitochondrial-derived peptide connected to energy balance and exercise adaptation. |
| Mitochondrial oxidative stress | SS-31 | Targets mitochondrial membrane and cardiolipin-associated pathways. |
| Adipocyte enzyme signaling | 5-Amino-1MQ | Studied through NNMT inhibition and adipocyte energy handling. |
| Cellular redox and energy metabolism | NAD+ | Foundational cofactor for mitochondrial function, redox biology and sirtuin-related pathways. |
Metabolic peptide research is sensitive to purity, identity, degradation and storage variability. Researchers should evaluate the supplier before evaluating the compound.
| Standard | Why It Matters |
|---|---|
| Batch-specific COA | Connects each lot to analytical documentation and improves traceability. |
| HPLC purity verification | Supports purity evaluation and impurity visibility. |
| Mass spectrometry identity confirmation | Supports molecular identity confirmation, especially for complex peptides. |
| Clear lot numbers | Improves repeatability, documentation discipline and internal laboratory tracking. |
| Storage and handling guidance | Reduces avoidable degradation, moisture exposure and freeze-thaw variability. |
| Research-use-only labeling | Keeps the material separated from consumer, clinical, supplement, cosmetic or therapeutic positioning. |
These product pages are included for researchers who need product-level documentation, lot-level review, COA access and research-use-only material information.
These answers cover the most common fat-loss peptide, metabolic peptide and body-composition research questions in Canada.
Current research frequently focuses on incretin-based compounds such as retatrutide and tirzepatide, amylin-pathway compounds such as cagrilintide, visceral-adiposity models such as tesamorelin, and mitochondrial or cellular metabolism compounds such as MOTS-C, SS-31, 5-Amino-1MQ and NAD+.
Retatrutide is not a GLP-1-only peptide. It is an investigational triple agonist designed to activate GIP, GLP-1 and glucagon receptor pathways, making it mechanistically different from single-pathway GLP-1 models.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Retatrutide is a triple agonist designed to activate GIP, GLP-1 and glucagon receptors. The added glucagon receptor pathway is the key mechanistic difference.
The materials discussed on this page are presented strictly for laboratory research and are not represented as approved drugs, foods, supplements, cosmetics or consumer health products. Luxara Labs materials are not intended for human or veterinary use.
No. Mitochondrial peptides such as MOTS-C and SS-31 are studied for energy-system function, metabolic flexibility, oxidative stress and mitochondrial signaling. They should not be described as direct fat-burning agents.
Cagrilintide is a long-acting amylin analogue studied for satiety signaling, gastric-emptying models and combination research with GLP-1 pathway compounds. Its relevance is the amylin and appetite-regulation axis.
Tesamorelin is included because it has been studied in visceral adipose tissue and body-composition models through GHRH and GH/IGF-1 pathway signaling. It is mechanistically different from appetite-focused incretin compounds.
In research discussions, peptide stacks refer to models where more than one pathway is studied together, such as incretin plus amylin signaling or mitochondrial plus cellular metabolism pathways. This page does not provide stacking instructions or use recommendations.
High purity supports cleaner interpretation, stronger repeatability and lower risk of confounding from impurities. Researchers should review batch-specific COAs, HPLC purity documentation and mass spectrometry identity confirmation where available.
Luxara Labs ships research-use-only materials across Canada and provides USA-facing research resources and shipping guidance. US-bound shipments may be subject to customs, FDA-related import screening and carrier review.
These references support the retatrutide, tirzepatide, cagrilintide, tesamorelin, MOTS-C, SS-31, 5-Amino-1MQ, NAD+, mitochondrial, adipocyte and metabolic research context discussed on this page.
Join our list and get an instant 10% discount code — valid for first-time buyers.
